Want to see IN:MEDICAMEQ full AI Analyst Report?

Medicamen Biotech Limited (MEDICAMEQ) Price & Analysis

0 Followers

MEDICAMEQ Stock Chart & Stats

₹366.90

-₹10.20(-1.97%)

At close: Jan 08 4:00 PM EST

₹366.90

-₹10.20(-1.97%)

Day’s Range― - ―

52-Week Range₹210.10 - ₹454.00

Previous CloseN/A

Volume10.37K

Average Volume (3M)3.36K

Market Cap

₹4.16B

Enterprise Value₹3.02K

Total Cash (Recent Filing)₹312.64M

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)40.3

Beta1.27

Next Earnings

Nov 06, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.31%

Share Statistics

EPS (TTM)8.01

Shares Outstanding13,562,815

10 Day Avg. Volume6,342

30 Day Avg. Volume3,361

Financial Highlights & Ratios

PEG Ratio1.06

Price to Book (P/B)1.08

Price to Sales (P/S)1.51

P/FCF Ratio-7.51

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Recent Revenue GrowthThe return to strong revenue growth in FY2026 indicates renewed demand for the company’s formulations after the prior-year decline. Sustained expansion would improve scale, support broader market reach, and provide a foundation for rebuilding earnings across its generic pharmaceutical portfolio.

Conservative Balance SheetModerate leverage gives Medicamen Biotech greater financial flexibility than a heavily indebted pharmaceutical business. A conservative capital structure can help the company fund operations, manage volatility, and pursue growth without excessive dependence on refinancing or costly external capital.

Broad Formulation PlatformA portfolio spanning multiple therapeutic segments and both Indian and international markets provides several avenues for demand and reduces reliance on a single product category. This breadth can support more resilient commercial growth as the company expands its generic formulation business.

Bears Say

Persistent Operating Cash OutflowsFour consecutive years of negative operating cash flow show that reported business activity is not consistently converting into cash. If this persists, the company may need continued funding for working capital and operations, reducing financial flexibility even while revenue and accounting profits remain positive.

Negative Free Cash FlowSustained negative free cash flow limits the internally generated funds available for investment, debt reduction, or shareholder returns. The sharp FY2026 outflow increases the importance of improving cash conversion and controlling cash requirements so growth does not create ongoing financing pressure.

Weakening ProfitabilityThe decline in net income and return on equity suggests that the expanding capital base is producing less profit than in earlier periods. Weaker profitability can constrain reinvestment capacity and indicates that revenue growth has not yet translated into consistently stronger earnings quality.

Medicamen Biotech Limited News

Medicamen Biotech Gets NSE Caution Over Compliance Observations

The latest announcement is out from Medicamen Biotech Limited ( ($IN:MEDICAMEQ) ). Medicamen Biotech Limited has disclosed that...

7M ago

MEDICAMEQ FAQ

What was Medicamen Biotech Limited’s price range in the past 12 months?

Medicamen Biotech Limited lowest stock price was ₹210.10 and its highest was ₹454.00 in the past 12 months.

What is Medicamen Biotech Limited’s market cap?

Medicamen Biotech Limited’s market cap is ₹4.16B.

When is Medicamen Biotech Limited’s upcoming earnings report date?

Medicamen Biotech Limited’s upcoming earnings report date is Nov 06, 2026 which is in 54 days.

How were Medicamen Biotech Limited’s earnings last quarter?

Medicamen Biotech Limited released its earnings results on Aug 14, 2026. The company reported ₹1.562 earnings per share for the quarter.

Is Medicamen Biotech Limited overvalued?

According to Wall Street analysts Medicamen Biotech Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Medicamen Biotech Limited pay dividends?

Medicamen Biotech Limited pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.31%. See more information on Medicamen Biotech Limited dividends here

What is Medicamen Biotech Limited’s EPS estimate?

Medicamen Biotech Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Medicamen Biotech Limited have?

Medicamen Biotech Limited has 13,562,815 shares outstanding.

What happened to Medicamen Biotech Limited’s price movement after its last earnings report?

Medicamen Biotech Limited reported an EPS of ₹1.562 in its last earnings report. Following the earnings report the stock price went down -0.824%.

Which hedge fund is a major shareholder of Medicamen Biotech Limited?

Currently, no hedge funds are holding shares in IN:MEDICAMEQ

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Medicamen Biotech Limited

Medicamen Biotech Limited, established in 1993 and headquartered in New Delhi, India, is an Indian pharmaceutical firm primarily engaged in the manufacturing and distribution of a diverse range of medicinal formulations. Its product line encompasses various dosage formats, including tablets, capsules, liquid and dry syrups, and topical ointments. The company further extends its portfolio to specialized items such as oral rehydration solutions, mouthwashes, and dental care products.